Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ancora Heart, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>18 years
Subjects with clinically significant mitral regurgitation (MR 2+ and above)
Ejection Fraction ≥ 25%
Stable cardiac medical regimen for heart failure for at least 1 month
Stable NYHA Classification for at least 1 month
Subject is eligible for cardiac surgery
The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
You may not be if
Myocardial infarction within 90 days of the intended treatment with the device
Prior surgical, transcatheter, or percutaneous mitral valve intervention
Any intervention for coronary artery disease (CAD) within the last 30 days prior to treatment, or unrevascularized multivessel coronary disease
Hemodynamic instability or the need for emergent surgery
Non-ambulatory NYHA Class IV symptoms of heart failure or subjects requiring IV inotropic support
Subjects in whom sufficient quality of echocardiography (TTE and TEE) cannot be obtained
Echocardiography evidence of primary mitral valve disease causing MR or MS,
Evidence of mitral valve stenosis with an estimated valve area less than 3.0 cm2
Mitral valve prosthesis or pathology that would prevent adequate function of the GDS Accucinch System
Estimated GFR of \<30ml/min/1.73m2
Greater than mild mitral annular calcification observed by fluoroscopy
Presence of aortic valve prosthesis
Moderate to severe aortic valve stenosis or calcification observed by echocardiography or fluoroscopy
Severe aortic arch calcification or mobile aortic atheroma observed by echocardiography or fluoroscopy
Active bacterial endocarditis
History of bleeding diathesis or coagulopathy
History of stroke within the prior 6 months
Subjects in whom anticoagulation is contraindicated
Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device.
Concurrent medical condition with a life expectancy of less than 12 months
Currently participating in an investigational study
Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. severe chronic obstructive pulmonary disease, hepatic failure, immunological abnormalities, and hematological abnormalities)
Subjects with indication for concomitant surgery such as coronary artery bypass graft (CABG), aortic valve reconstruction or replacement, tricuspid repair or replacement, left ventricular remodeling surgery and congenital repair
Any cardiac resynchronization therapy within the last 3 months prior to treatment
Subjects on high dose steroids or immunosuppressant therapy
Female subjects who are pregnant, of child bearing potential or lactating
Subjects who are unable or unwilling to comply with the follow-up schedule and requirements